The NextGen PulmoCore 12 Gene Panel – PD-L1 22C3 at Metropolis Healthcare is a precision molecular and immunotherapy test for lung cancer patients. It evaluates 12 clinically relevant lung cancer genes and assesses PD-L1 expression using the 22C3 clone to guide targeted therapy and immunotherapy decisions. Metropolis Healthcare combines high-depth Next-Generation Sequencing with validated IHC techniques to provide accurate, actionable insights. This test is ideal for patients with confirmed or suspected lung cancer requiring personalized treatment planning.
Price:
Rs. 30,000.00
Sample Type: Tissue
Fasting Not Required
Notes:N8227
Frequently Asked Questions (FAQ's):
What does the PulmoCore 12 Gene Panel – PD-L1 22C3 at Metropolis Healthcare include?
It analyzes 12 key lung cancer–related genes and measures PD-L1 expression using the 22C3 clone.
How does Metropolis Healthcare perform this lung cancer panel?
Metropolis Healthcare uses high-depth NGS for genomic analysis and validated 22C3 immunohistochemistry for PD-L1 scoring.
Who should consider taking this test at Metropolis Healthcare?
Patients with confirmed or suspected lung cancer who require targeted therapy and immunotherapy guidance should consider this panel.
Is fasting required for this PulmoCore 12 Gene Panel at Metropolis Healthcare?
No fasting is needed; the test uses tumor tissue samples as advised by the clinician.
How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to detailed sequencing and PD-L1 evaluation.
Can this test at Metropolis Healthcare help guide immunotherapy decisions?
Yes, PD-L1 22C3 scoring helps determine potential response to immune checkpoint inhibitors.
How accurate is the gene and PD-L1 testing at Metropolis Healthcare?
Metropolis Healthcare ensures high precision with validated sequencing platforms and IHC protocols under strict quality control.
Does this panel support long-term treatment planning at Metropolis Healthcare?
Yes, it provides molecular and immunotherapy insights for personalized lung cancer management and therapy optimization.